I wrote more about the new, secondary cancer risk revelations connected with Revlimid in an article on our other daily, cancer related site, http://www.helpwithcancer.org/. yesterday:
The article focuses on the strange but true coincidence of two unrelated and FDA proved drugs–Avista, an osteoporosis drug, and Revlimid, an oral chemotherapy–both being “outed,” based on data revealed from two different sources in two different places, all on the same day. It turns out that long term use of either drug results in an 8% chance of the user developing a secondary cancer.
Feel good and keep smiling! Pat